Quince Therapeutics, Inc. — filing identity and reporting period
Important identity mismatch: The supplied filing is Cortexyme, Inc.’s Form 10-K, not a filing under Quince Therapeutics, Inc. It covers the fiscal year ended December 31, 2021; the financial results below are annual, not standalone fourth-quarter results. The filing was signed March 1, 2022.
Business context and key financial metrics
Cortexyme was a clinical-stage biopharmaceutical company developing gingipain inhibitors and other candidates for Alzheimer’s disease and potential oncology, periodontal-disease, and coronavirus applications. It had no approved products and generated no product revenue.
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $60.8 million | $61.3 million |
| General and administrative expense | $29.5 million | $17.6 million |
| Operating loss | $90.3 million | $78.9 million |
| Net loss | $89.9 million | $76.8 million |
| Net loss per share, basic and diluted | $3.03 | $2.63 |
| Net cash used in operating activities | $62.9 million | $50.8 million |
Margins are not meaningful because the company had no revenue. At December 31, 2021, cash and cash equivalents were $69.7 million, short-term investments $37.1 million, and long-term investments $19.9 million—$126.7 million combined. Current assets were $111.7 million and current liabilities $14.2 million. Total liabilities were $14.6 million, including operating lease liabilities; the filing reports no borrowings or funded debt. Stockholders’ equity was $118.6 million.
Cash and cash equivalents increased $2.9 million during 2021. Financing provided $6.8 million, primarily from stock-option exercises; investing provided $59.0 million, principally reflecting investment maturities net of purchases. The company reported $29.9 million of stock-based compensation expense.
Material changes versus the prior comparable period
- Net loss widened by 17% to $89.9 million. Operating expenses rose 14.5%, mainly because G&A increased $11.9 million, including higher headcount-related and stock-based compensation costs.
- R&D expense was nearly flat overall, but spending shifted: atuzaginstat (COR388) direct costs fell $16.5 million as the GAIN trial substantially concluded, while COR588 direct costs rose $3.0 million as its Phase 1 program began.
- Operating cash use increased $12.1 million year over year. Cash, cash equivalents, and investments declined from $184.3 million at year-end 2020 to $126.7 million at year-end 2021.
- Common shares outstanding rose to 30.1 million from 29.5 million. The company’s stock-return index fell to 38.37 at year-end 2021 from 84.46 at year-end 2020 (initial investment index = 100).
Outlook, management commentary, risks, and unusual items
- GAIN trial and COR388: The 643-participant Phase 2/3 GAIN trial did not meet statistical significance on its co-primary cognitive and functional endpoints in the overall population. A prespecified subgroup with detectable P. gingivalis DNA showed a dose-response signal on the cognitive measure, but not significant benefit on the other co-primary endpoint. COR388 was associated with dose-related liver enzyme elevations; two participants in the high-dose group also had bilirubin elevations.
- Regulatory hold: The FDA imposed a partial hold on the GAIN open-label extension in February 2021 over hepatic events, then a full clinical hold on the COR388 Alzheimer’s IND on January 25, 2022. Management said it would prioritize COR588 for Alzheimer’s and explore COR388 in non-CNS indications; those plans remain subject to regulatory review and development risk.
- Pipeline plans: COR588 began a Phase 1 SAD/MAD trial in Australia in August 2021, with results expected in Q2 2022 and a Phase 2 study planned thereafter. Management also planned to seek an oncology IND for COR388 and continue preclinical work on other pipeline candidates. These are forward-looking plans, not assured outcomes.
- Cost reduction and leadership: Following the clinical hold, the board approved a workforce reduction of approximately 53%, with most cuts planned by March 2022 and the remainder by July. Management estimated up to $2.1 million in severance-related cash costs and annualized 2022 operating-expense savings of approximately $8–$8.5 million, excluding stock compensation and one-time costs. CEO Casey Lynch and Chief Scientific Officer Stephen Dominy resigned effective January 28, 2022; severance payments were $604,000 and $326,250, respectively.
- Liquidity outlook and financing: Management estimated existing capital resources would fund planned operations through 2024, based on current plans and assumptions. The company also stated it would need substantial additional capital over time. Its $150 million at-the-market sales facility had no 2021 sales; it sold 51,769 shares for approximately $608,000 net proceeds from January 1 through February 24, 2022.
- Other risks and contingencies: Development, clinical-trial, safety, regulatory, manufacturing, funding, intellectual-property, and competition risks are substantial. COVID-19 had not caused significant supply disruption or material financial impact to date, but could affect trials and suppliers. The company disclosed $15.6 million in cancellable future contract commitments and $7.7 million in accrued vendor expenditures at year-end. It reported no material pending litigation.
- Audit and controls: The auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; management also concluded disclosure controls and internal controls were effective.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied 10-K is for Cortexyme, Inc. (ticker CRTX), not Quince Therapeutics, Inc.
- Review the FDA’s basis and any subsequent developments regarding the full COR388 clinical hold, including whether any non-CNS COR388 development may proceed.
- Assess the final GAIN trial data, including the overall-population endpoint failures, subgroup findings, and hepatic safety results.
- Verify COR588 Phase 1 results and whether the proposed Phase 2 development, timing, and funding remain on track.
- Track actual cash burn, investment values, ATM issuance/dilution, and whether the projected runway through 2024 remains supportable after restructuring.
- Compare realized headcount reductions, severance costs, and operating-expense savings with management’s estimates.